GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2015-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.115.305447PMID 25908765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes

  2014cited by this paper
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

  2014cited by this paper
• Insulin‐Induced Changes in Microvascular Vasomotion and Capillary Recruitment are Associated in Humans

  2014cited by this paper
• Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

  2014cited by this paper
• GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

  2014cited by this paper
• GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.

  2014cited by this paper
• Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients

  2014cited by this paper
• Glucagon-Like Peptide 1 Recruits Muscle Microvasculature and Improves Insulin’s Metabolic Action in the Presence of Insulin Resistance

  2014cited by this paper
• Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation

  2013cited by this paper
• GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

  2013cited by this paper
• Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment.

  2013cited by this paper
• Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.

  2013cited by this paper
• Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism

  2012cited by this paper
• Regulation of Muscle Microcirculation in Health and Diabetes

  2012cited by this paper
• Cardiovascular biology of the incretin system.

  2012cited by this paper
• Insulin‐Induced Microvascular Recruitment in Skin and Muscle are Related and Both are Associated with Whole‐Body Glucose Uptake

  2012cited by this paper
• Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

  2012cited by this paper
• Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans

  2011cited by this paper
• Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver

  2009cited by this paper
• Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo.

  2009cited by this paper
• Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise

  2009cited by this paper
• Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model.

  2009cited by this paper
• Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.

  2007cited by this paper
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• Effects of the nitric oxide synthase inhibitor L‐NMMA on cerebrovascular and cardiovascular responses to hypoxia and hypercapnia in humans

  2007cited by this paper
• Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism.

  2005cited by this paper
• Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

  2005cited by this paper
• Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• Involvement of sympathetic nerve activity in skin blood flow oscillations in humans.

  2003cited by this paper
• Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia.

  2002cited by this paper
• Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.

  2002cited by this paper
• Impaired Skin Capillary Recruitment in Essential Hypertension Is Caused by Both Functional and Structural Capillary Rarefaction

  2001cited by this paper
• Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.

  2001cited by this paper
• Wavelet analysis of oscillations in the peripheral blood circulation measured by laser Doppler technique

  1999cited by this paper
• Microvascular function relates to insulin sensitivity and blood pressure in normal subjects.

  1999cited by this paper
• Wavelet-based analysis of human blood-flow dynamics

  1998cited by this paper
• EFFECT OF NG‐M0N0METHYL‐L‐ARGININE ON THE MICROCIRCULATION OF RAT SKIN

  1997cited by this paper
• GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery.

  1993cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Molecular damage associated with ageing drives inflammation in cardiovascular disease.

  2026cites this paper
• Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias

  2025cites this paper
• An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

  2025cites this paper
• Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes

  2025cites this paper
• GLP-1RA and the possible skin aging

  2025cites this paper
• Role of GLP-1 receptor agonists in sepsis and their therapeutic potential in sepsis-induced muscle atrophy (Review)

  2025cites this paper
• Exploring receptors for pro-resolving and non-pro-resolving mediators as therapeutic targets for sarcopenia.

  2025cites this paper
• Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study

  2025cites this paper
• Adipose tissue in older individuals: a contributing factor to sarcopenia.

  2024cites this paper
• GLP-1 receptor agonists and vascular protection.

  2024cites this paper
• Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023

  2024cites this paper
• Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Relevance of Peptide Homeostasis in Metabolic Retinal Degenerative Disorders: Curative Potential in Genetically Modified Mice

  2022cites this paper
• The contributory role of vascular health in age‐related anabolic resistance

  2021cites this paper
• Vasomotion analysis of speed resolved perfusion, oxygen saturation, red blood cell tissue fraction, and vessel diameter: Novel microvascular perspectives

  2021cites this paper
• The Role of Gasotransmitters in Gut Peptide Actions

  2021cites this paper
• Exendin‐4, a GLP‐1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia–reperfusion injury

  2020influential citation
• Cardiovascular effects of GLP-1 receptor agonists: from mechanistic studies in humans to clinical outcomes.

  2019cites this paper
• The effect of glucagon‐like peptide‐1 and glucagon‐like peptide‐2 on microcirculation: A systematic review

  2019cites this paper
• Insulin Resistance and Atherosclerosis: Implications for Insulin Sensitizing Agents.

  2019cites this paper
• Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

  2019cites this paper
• Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients

  2018cites this paper
• Molecular and clinical roles of incretin-based drugs in patients with heart failure

  2018cites this paper
• Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.

  2018cites this paper
• Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats

  2017cites this paper
• Novel mechanisms of action of Glucagon-like peptide-1 (GLP-1) receptor agonists on the skeleton

  2017cites this paper
• Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus

  2017cites this paper
• Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

  2017cites this paper
• Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.

  2016cites this paper
• Acute renal haemodynamic effects of glucagon‐like peptide‐1 receptor agonist exenatide in healthy overweight men

  2016cites this paper
• GLP-1–Based Therapies Have No Microvascular Effects in Type 2 Diabetes MellitusHighlights

  2016cites this paper
• The Skeletal Muscle Microvasculature and Its Effects on Metabolism

  2016cites this paper
• Decreased cerebral blood flow in T 2 DM patients is not improved by treatment with liraglutide

  2016cites this paper
• GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.

  2016cites this paper
• Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.

  2016cites this paper
• Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance

  2015cites this paper